The deal size was increased to $250M from $175M and priced inside the $25.00-$27.00 target range. BofA, Evercore ISI, Goldman Sachs, Stifel, Wells Fargo, LifeSci Capital and H.C. Wainwright are acting as joint book running managers for the offering.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics Halts Common Stock Offering
- Mineralys Therapeutics announces $175M common stock offering
- 3 Best Stocks to Buy Now, 9/2/2025, According to Top Analysts
- Jefferies expects Mineralys stock to trade up following AstraZeneca data
- Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones